Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy Brainstorm Cell Therapeutics stock (BCLI)

Buy Brainstorm Cell Therapeutics stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Brainstorm Cell Therapeutics is a biotechnology business based in the US. Brainstorm Cell Therapeutics shares (BCLI) are listed on the NASDAQ and all prices are listed in US Dollars. Brainstorm Cell Therapeutics employs 29 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Brainstorm Cell Therapeutics stock

Top pick for advanced traders

Go to site
Get up to $5,000 cash
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Best for beginners

Go to site
Get up to $1,000 in stock
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • No-cost financial planning and automated investing

Our pick for cash sweep

Go to site
Advanced charts and trading tools
  • Trade stocks, ETFs and equity options without commission and $0 option contract fees
  • Earn up to 8.1% APY on your uninvested cash
  • Get a 1.5% match in cash on transferred assets up to $300 or up to 15 free fractional shares worth between $2 and $2,000

How to buy Brainstorm Cell Therapeutics stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – BCLI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Brainstorm Cell Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Finder Score: 4.4 / 5: ★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
Stocks, Options, Mutual funds, ETFs, Alternatives
Get up to $1,000 in stock
Commission-free stocks, ETFs and options, with no options per-contract fees. Plus, a no-cost robo-advisor and complimentary access to certified financial planners (CFPs).
Finder Score: 4.3 / 5: ★★★★★
Stocks, Options, ETFs
Up to 8.10%
Choose a 1.5% match or up to 15 free fractional shares
No commission stock, ETF and options trades, with $0 equity options contract fees, low margin rates and advanced trading tools.
Finder Score: 4.2 / 5: ★★★★★
Stocks, Bonds, Options, ETFs, Cryptocurrency, Alternatives, Treasury Bills, High-yield cash account
Get up to $10,000 and transfer fees covered
Build a diversified portfolio of stocks, bonds, options, ETFs, crypto and alternative assets, with a high-yield cash account and options contract rebates.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Brainstorm Cell Therapeutics stock price (NASDAQ: BCLI)

Use our graph to track the performance of BCLI stocks over time.

Brainstorm Cell Therapeutics shares at a glance

Information last updated 2024-07-07.
Latest market close$0.35
52-week range$0.13 - $2.07
50-day moving average $0.45
200-day moving average $0.37
Wall St. target price$2.50
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.31

Is it a good time to buy Brainstorm Cell Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Brainstorm Cell Therapeutics price performance over time

Historical closes compared with the close of $0.351 from 2024-07-10

1 week (2024-07-05) -4.12%
1 month (2024-06-12) -23.03%
3 months (2024-04-12) -39.90%
6 months (2024-01-12) 7.37%
1 year (2023-07-12) -82.45%
2 years (2022-07-12) -86.65%
3 years (2021-07-12) 3.56
5 years (2019-07-12) 4.48

Brainstorm Cell Therapeutics financials

Gross profit TTM $0
Return on assets TTM -209.02%
Return on equity TTM -1121.9%
Profit margin 0%
Book value $-0.08
Market Capitalization $29.1 million

TTM: trailing 12 months

Brainstorm Cell Therapeutics share dividends

We're not expecting Brainstorm Cell Therapeutics to pay a dividend over the next 12 months.

Have Brainstorm Cell Therapeutics's shares ever split?

Brainstorm Cell Therapeutics's shares were split on a 1:15 basis on 15 September 2014. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Brainstorm Cell Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Brainstorm Cell Therapeutics shares which in turn could have impacted Brainstorm Cell Therapeutics's share price.

Brainstorm Cell Therapeutics share price volatility

Over the last 12 months, Brainstorm Cell Therapeutics's shares have ranged in value from as little as $0.134 up to $2.073. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Brainstorm Cell Therapeutics's is 0.36. This would suggest that Brainstorm Cell Therapeutics's shares are less volatile than average (for this exchange).

Brainstorm Cell Therapeutics overview

Brainstorm Cell Therapeutics Inc. , a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York. .

Frequently asked questions

What percentage of Brainstorm Cell Therapeutics is owned by insiders or institutions?
Currently 9.051% of Brainstorm Cell Therapeutics shares are held by insiders and 5.152% by institutions.
How many people work for Brainstorm Cell Therapeutics?
Latest data suggests 29 work at Brainstorm Cell Therapeutics.
When does the fiscal year end for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics's fiscal year ends in December.
Where is Brainstorm Cell Therapeutics based?
Brainstorm Cell Therapeutics's address is: 1325 Avenue of Americas, New York, NY, United States, 10019
What is Brainstorm Cell Therapeutics's ISIN number?
Brainstorm Cell Therapeutics's international securities identification number is: US10501E2019
What is Brainstorm Cell Therapeutics's CUSIP number?
Brainstorm Cell Therapeutics's Committee on Uniform Securities Identification Procedures number is: 10501E102

More guides on Finder

Ask a Question provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site